CHICA­GO — Not long ago, there were hopes that a new class of can­cer drugs would re­peat the suc­cess of Keytru­da. In­stead, it seems more...

The FDA is fur­ther ex­plain­ing to cell and gene ther­a­py de­vel­op­ers the types of pri­or knowl­edge com­pa­nies can lever­age for clin­i­cal, non­clin­i­cal and man­u­fac­tur­ing-re­lat­ed work...

The Bay Area start­up NewLim­it has closed one of biotech's largest pri­vate fi­nanc­ings of 2026 and ex­pects to start hu­man test­ing next year for its...

Eli Lil­ly is giv­ing a group of hos­pi­tals five days to com­ply with its new claims da­ta pol­i­cy or risk los­ing their 340B dis­counts.

Some...

A Seat­tle-based non­prof­it known for ba­sic brain re­search is launch­ing a $400 mil­lion ini­tia­tive to trans­late its knowl­edge in­to drug de­vel­op­ment for neu­rode­gen­er­a­tive dis­eases, in­clud­ing...